Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) produced a 51.31% rally since recording the worst price of $9.55. Thanks to the latest 4.03% increase, it now trades at $14.45. Throughout the trading on 4/22/2019, the share price floated between $13.35 and $13.93. This company shares are 78.2% off its target price of $25.75 and the current market capitalization stands at $1.4B. The recent change has given its price a 4.06% lead over SMA 50 and -55.12% deficit over its 52-week high. The stock witnessed 2.48% gains, 18.83% gains and -4.3% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MNTA’s volatility during a week at 4.8% and during a month it has been found around 4.91%.

Momenta Pharmaceuticals, Inc. (MNTA) Top Holders

Institutional investors currently hold around $1.33 billion or 98% in MNTA stock. Look at its top three institutional owners: Fmr Llc owns $205.17 million in Momenta Pharmaceuticals, Inc., which represents roughly 14.65% of the company’s market cap and approximately 15.48% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 13,775,141 shares of the stock are valued at $191.34 million. The third largest holder is Vanguard Group Inc, which currently holds $134.93 million worth of this stock and that ownership represents nearly 9.64% of its market capitalization.

Momenta Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 98 institutional holders increased their position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by some 26,285,565 shares, 77 decreased positions by 8,536,656 and 14 held positions by 60,549,367. That puts total institutional holdings at 95,371,588 shares, according to SEC filings. The stock grabbed 27 new institutional investments totaling 3,019,314 shares while 37 institutional investors sold out their entire positions totaling 4,919,217 shares.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Insider Trades

Multiple company employees have indulged in significant insider trading. Momenta Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP, Chief Medical Officer Arroyo Santiago has sold 8,119 shares of Momenta Pharmaceuticals, Inc. (MNTA) in the trading session dated Apr. 09, 2019. These shares are worth $121,785 and were traded at $15 each. The SEC filing shows that FIER IAN performed a sale of 4,163 shares. The Chief Mfg and Program Officer disposed these shares by way of transaction on Apr. 09, 2019. The company’s shares were given away at $15 per share worth to an income of some $62,445 to the account of FIER IAN.

Chief HR and Inf. Officer, BELTRAMELLO JO ANN, sold 29,167 common shares of Momenta Pharmaceuticals, Inc. (MNTA) in the open market. In a transaction dated Mar. 18, 2019, the shares were put up for sale at an average price of $14.2, raking in a sum of $414,171. After this sale, 112,166 common shares of MNTA are directly owned by the insider, with total stake valued at $1,620,799.

In the transaction dated Mar. 18, 2019, a great number of shares sold came courtesy the Director; DOWNEY BRUCE disposed a total of 13,000 shares at an average price of $14.51, amounting to approximately $188,630. The insider now directly owns 28,234 shares worth $407,981.

Momenta Pharmaceuticals, Inc. (MNTA) Analyst Guide

Several analysts have released their opinion on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), with 1 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation [T1].